Combating Drug Resistance: A New Class of Anticancer Drugs Takes Aim at Cancer’s Evasive Tactics
A Multi-Targeted Family of Drugs That Kills Cancer Cells and Is Safe for Normal Cells
We are pleased to share this SuperCrowd Voices from the Community post with you. SuperCrowd Voices posts represent the views of our guest authors, not The Super Crowd, Inc., a public benefit corporation. Manage the volume of emails you receive from us by clicking here. Interested in sharing your voice? Click here.
Most Fatal Cancers Are Drug-Resistant
Across our lifespans, approximately 1 in 9 men and 1 in 12 women will die of cancer. In 2022, this resulted in over 600,000 deaths. Most of these deaths occur because tumors become resistant to treatment. Resistance is the reason why even the most promising treatments stop working; it’s why cancers come back. It is seen across essentially all aggressive cancer types. Drug resistance is one of the greatest obstacles to improving cancer treatment outcomes.
A novel drug family, called ‘BRG drugs’, currently in development, works to overcome both intrinsic (innate to the tumor) and acquired (developed over time) resistance in tumors. This new drug family represents a major step forward in achieving a more durable treatment or cure—and a significant commercial opportunity.
A New Kind of Drug: Multi-Targeted Action
Most recently developed anticancer drugs, known as ‘targeted’ anticancer agents, are designed to hit one target; that is, a specific mutated protein or a key element or node in a single pathway. That approach can work—for a while. But cancer doesn’t rely on just one scheme. It rewires entire systems to survive.
BRG drugs deliver two active ingredients, both of which are FDA-approved when used as components of other drugs. These ingredients address the underlying biology that allows cancer cells to evade treatment. Early data suggest effectiveness against multiple tumor types, including those with limited therapeutic options such as lung cancer, castration-resistant prostate cancer, ovarian cancer, triple negative breast cancer, mesothelioma, pancreatic cancer, and myeloblastic leukemia. With resistance being a central failure point across nearly all standard-of-care regimens, the addressable market is both broad and underserved.
How Members of One Drug Family Tackle Drug Resistance
How can a single drug address something as complex as cancer drug resistance? The answer lies in how BRG drugs fundamentally redefine the way we intervene in cancer biology. BRG drugs use a multi-targeted strategy to reprogram multiple internal “cellular machines” and pathways, including cancer-related systems like ones called the MAPK/ERK cascade and PI3K/AKT/mTOR pathway. This approach allows BRG drug ingredients to block cancer processes called ‘hallmarks of cancer’, restore normal cell function and suppress altered system function that allows cancer-driven tumor aggression, invasion, and/or metastasis.
BRG drugs interfere with the signaling molecules that tumors rely on to adapt and survive under therapeutic pressure. These molecules help cancer cells shift their phenotype (identity), bypass targeted therapies, and resist chemotherapy. BRG drugs cut off cancer’s escape routes.
The p53 protein, often called the “guardian of the genome,” is a powerful tumor suppressor protein that is frequently neutralized in cancers. BRG drugs increase p53 levels in the nucleus, where it’s most active, and prevent it from being co-opted to promote tumor growth. They reactivate a substantial subset of mutant p53 proteins, thereby promoting normal protein function. By restoring this master regulator, BRG drugs tip the cellular balance back toward normalcy and induce regulated tumor cell death.
In short, BRG drugs hit multiple targets in a coordinated fashion to remove the ability of cancer cells to fight back—thereby beating resistance at its roots.
Precision That Protects; Why It Matters
What truly sets BRG drugs apart is not only how effectively they attack cancer, but how safely they spare healthy tissue. One BRG drug active ingredient is a cell-protective ingredient—an active component that’s been shown to kill cancer cells while protecting normal cells in experimental animals and people. This selectivity can be translated to result in lower toxicity, better tolerability, and the potential for broader, more sustained use.
By overcoming the biology of resistance itself, BRG drugs have the potential to extend the impact of existing therapies, improve patient outcomes, and even make the concept of durable remission—or cure—a real possibility.
BRG drugs represent a platform-level innovation. A single BRG compound can support treatment across multiple tumor types. The full BRG drug family can redefine how we approach cancer altogether.
Cancer doesn’t just take a physical toll – it takes an emotional one as well; the cycles of treatment, hope, regression, and uncertainty can be devastating. Thus, BRG drugs offer new hope for all us vulnerable to cancer – they can change the trajectory of cancer care.
Moving Forward
BRG drug Intellectual Property rights are owned by The Burlington HC Research Group, Inc. (BHCRG), and this business is being built for the sole purpose of bringing these drugs to market. Testing to obtain Investigational New Drug status is well advanced, and remaining tasks will be completed as funding becomes available. Partnering with pharmaceutical companies is also being pursued, with the potential to license the BRG drug family if the right opportunity arises. Several well-known companies have expressed early interest in learning more about this drug family. As part of these efforts, BHCRG soon will be launching a crowdfunding campaign.
Dale M. Walker’s Bio
Dale M. Walker is a veterinarian with advanced training in veterinary and human pathology. In partnership with her husband, her early work focused on drug safety testing using cell culture and rodent models. Unusual challenges encountered in the course of this work required development of innovative solutions that were based upon integrating information from the fields of toxicology, DNA biology, and cellular stress response biochemistry. This work brought to her attention the therapeutic potential of one of the active ingredients delivered by BRG drugs, and further work led to the discovery of the BRG drug family. For the last decade, she and her husband have focused exclusively on advancing this family of drugs so that their benefits to people and animals can be realized.
Links:
Website: www.bhcrg.com
LinkedIn: linkedin.com/in/dale-walker-267a0443
Substack: combatcancerdrugresistance.substack.com
Max-Impact Members
The following Max-Impact Members provide valuable financial support:
Carol Fineagan, Independent Consultant | Lory Moore, Lory Moore Law | Marcia Brinton, High Desert Gear | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Ralf Mandt, Next Pitch | Scott Thorpe, Philanthropist | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Add Your Name Here
Upcoming SuperCrowd Event Calendar
If a location is not noted, the events below are virtual.
SuperCrowdLA: We’re going to be live in Santa Monica, California, May 1-3. Plan to join us for a major, in-person event focused on scaling impact. Sponsored by Digital Niche Agency, ProActive Real Estate and others. This will be a can’t-miss event. Has your business been impacted by the recent fires? Apply now for a chance to receive one of 10 free tickets to SuperCrowdLA on May 2nd and 3rd and gain the tools to rebuild and grow!
Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on May 20, 2025, at 1:00 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.
SuperCrowdHour, May 21, 2025, at 1:00 PM Eastern. Devin Thorpe, Champion of Social Good and CEO of The Super Crowd, Inc., will lead a session on "The Secret to Higher Investment Returns via Impact Crowdfunding." He’ll share powerful strategies and real-world examples that show how aligning your investments with your values can lead to strong financial and social returns. If you're an investor looking to maximize impact or curious about the growing world of impact crowdfunding, this is a session you won’t want to miss! Don’t miss it!
SuperCrowd25, August 21st and 22nd: This two-day virtual event is an annual tradition but with big upgrades for 2025! We’ll be streaming live across the web and on TV via e360tv. Soon, we’ll open a process for nominating speakers. Check back!
Community Event Calendar
Successful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.
Crowdfunding Addict: Lessons Learned from a Year of Daily Investments, Wednesday, May 14, 2025, at 2:00 PM ET.
Regulated Investment Crowdfunding Summit 2025, Crowdfunding Professional Association, Washington DC, October 21-22, 2025.
Call for community action:
Please show your support for a tax credit for investments made via Regulation Crowdfunding, benefitting both the investors and the small businesses that receive the investments. Learn more here.
If you would like to submit an event for us to share with the 9,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.
Manage the volume of emails you receive from us by clicking here.
 | A guest post by
|